Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Patient and Health Care Provider Perspectives of Naloxone
Miscellaneous
Miscellaneous
Miscellaneous
N/A
Hande, Karen
VICCSUPP2068
Pattern of Changes in Immune Profile in the Setting of Chimeric Antigen Receptor T-Cell Therapy
Miscellaneous
Miscellaneous
Miscellaneous
N/A
Oluwole, Olalekan
VICCCTT2074
JHMIRB: Prospective Clinical Study of the Relationship Between Cancer Driving Mutations Found in Endometriotic Implants and Development of Progesterone Resistance
Gynecologic
Gynecologic
Gynecologic
N/A
Tran, Kaylon
VICCGYN2091
Discovering Outcomes in Clonal Hematopoiesis: The Clonal Hematopoiesis and Inflammation in VasculaturE (CHIVE) Registry and Biorepository
Hematologic
Hematologic
Hematologic
N/A
Bick, Alexander
VICCHEM20123
Impact of DHT on Swallowing Physiology in HNCa Patients
Head/Neck
Head/Neck
Head/Neck
N/A
Topf, Michael
VICCHN2102
Laryngeal Cancer Treatment Decision-Making: A Conjoint Analysis of Post-Treatment Priorities
Not Available
N/A
Topf, Michael
VICCHN2201
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
Multiple Cancer Types
The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination
with talquetamab or teclistamab, and to characterize the safety and tolerability of
talquetamab or teclistamab when administered in combination with a PD-1 inhibitor.
with talquetamab or teclistamab, and to characterize the safety and tolerability of
talquetamab or teclistamab when administered in combination with a PD-1 inhibitor.
Multiple Myeloma,
Phase I
I
Baljevic, Muhamed
NCT05338775
VICCHEMP2253
RBS2418 Evaluation in Subjects With Unresectable or Metastatic Tumors
Phase I
Phase I
RBS2418 (investigational product) is a specific immune modulator, working through
ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor
immunity by increasing endogenous 2'-3'-cyclic guanosine monophosphate-adenosine
monophosphate (cGAMP) and adenosine triphosphate (ATP levels) and reducing adenosine
production in the tumors. RBS2418 has the potential to be an important therapeutic option for
subjects both as monotherapy and in combination with checkpoint blockade. This study is an
open-label, multi-site Phase 1a/1b study of RBS2418, a selective ENPP1 inhibitor, in
combination with pembrolizumab or as a monotherapy in subjects with advanced unresectable,
recurrent or metastatic tumors.
ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor
immunity by increasing endogenous 2'-3'-cyclic guanosine monophosphate-adenosine
monophosphate (cGAMP) and adenosine triphosphate (ATP levels) and reducing adenosine
production in the tumors. RBS2418 has the potential to be an important therapeutic option for
subjects both as monotherapy and in combination with checkpoint blockade. This study is an
open-label, multi-site Phase 1a/1b study of RBS2418, a selective ENPP1 inhibitor, in
combination with pembrolizumab or as a monotherapy in subjects with advanced unresectable,
recurrent or metastatic tumors.
Phase I
I
Berlin, Jordan
NCT05270213
VICCPHI2289
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
Multiple Cancer Types
Clinical study to investigate the efficacy and safety of savolitinib in combination with
osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated,
MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed
on treatment with Osimertinib.
osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated,
MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed
on treatment with Osimertinib.
Lung,
Non Small Cell
III
Iams, Wade
NCT05261399
VICCTHO2219
